Key Takeaways
- • Adcendo ApS completed a $75 million Series C financing round on April 14, 2026, to advance its clinical-stage antibody-drug conjugate (ADC) pipeline targeting cancers with high unmet medical need.
- • The Series C round represents continued investor confidence in Adcendo's non-traditional ADC targets and platform, building on the company's $135 million Series B financing closed in November 2024 and earlier funding milestones.
- • Proceeds will support advancement of Adcendo's first-in-class and best-in-class ADC programs through clinical development, including programs that have achieved clinical milestone status such as ADCE-D01, which received FDA Fast Track designation in October 2025.
- • The funding trajectory—from €82 million Series A extension (2023) to $135 million Series B (November 2024) to $75 million Series C (April 2026)—demonstrates sustained institutional backing for the Copenhagen-based biotech's differentiated approach to ADC development.
Summary
Adcendo ApS, a Copenhagen-based biotech company focused on developing first-in-class and best-in-class antibody-drug conjugates (ADCs) for cancer treatment, successfully closed a $75 million Series C financing round on April 14, 2026. The capital raise extends the company's funding momentum as it progresses multiple ADC programs through clinical development stages targeting cancers with significant unmet medical needs.
The Series C funding builds on substantial prior institutional support for Adcendo's platform. The company raised an oversubscribed $135 million Series B round in November 2024, led by TCGX with participation from major life sciences investors including TPG Life Sciences Innovations, OrbiMed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), Logos Capital, and existing backers such as RA Capital Management, Novo Holdings, and KKR's Dawn Biopharma platform. Prior to that, Adcendo extended its Series A financing to €82 million in 2023 to enable transition into clinical development.
The company's differentiation in the competitive ADC space centers on targeting non-traditional pathways not broadly employed by first-generation approved ADCs. Recent clinical progress includes first-patient dosing in the Phase I/II ADCcelerate1 trial of ADCE-D01, and FDA Fast Track designation granted to ADCE-D01 for soft tissue sarcoma treatment in October 2025. The Series C proceeds will continue advancing this pipeline, including lead programs ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05, and A0401.
Michael Pehl, Chief Executive Officer of Adcendo, has emphasized that investor enthusiasm reflects both the momentum in the broader ADC therapeutic space and the company's experienced team and differentiated science platform. The cumulative funding secured across multiple rounds demonstrates sustained confidence from tier-one life sciences investors in Adcendo's ability to deliver clinical proof of concept for its novel ADC candidates.
The Series C funding builds on substantial prior institutional support for Adcendo's platform. The company raised an oversubscribed $135 million Series B round in November 2024, led by TCGX with participation from major life sciences investors including TPG Life Sciences Innovations, OrbiMed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), Logos Capital, and existing backers such as RA Capital Management, Novo Holdings, and KKR's Dawn Biopharma platform. Prior to that, Adcendo extended its Series A financing to €82 million in 2023 to enable transition into clinical development.
The company's differentiation in the competitive ADC space centers on targeting non-traditional pathways not broadly employed by first-generation approved ADCs. Recent clinical progress includes first-patient dosing in the Phase I/II ADCcelerate1 trial of ADCE-D01, and FDA Fast Track designation granted to ADCE-D01 for soft tissue sarcoma treatment in October 2025. The Series C proceeds will continue advancing this pipeline, including lead programs ADCE-T02 (Tissue Factor ADC), ADCE-D01 (uPARAP ADC), ADCE-B05, and A0401.
Michael Pehl, Chief Executive Officer of Adcendo, has emphasized that investor enthusiasm reflects both the momentum in the broader ADC therapeutic space and the company's experienced team and differentiated science platform. The cumulative funding secured across multiple rounds demonstrates sustained confidence from tier-one life sciences investors in Adcendo's ability to deliver clinical proof of concept for its novel ADC candidates.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.